Clinical Trial Update: A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan

View source ↗

Summary

A completed clinical trial evaluating how often adult chronic lymphocytic leukemia patients in Japan achieve undetectable minimal residual disease when treated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Rituxan (rituximab)
• Venclexta (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Chronic Lymphocytic Leukemia | Status: COMPLETED